PMID: 8947926Nov 1, 1996Paper

Use of a mu-antisense oligodeoxynucleotide as a mu opioid receptor noncompetitive antagonist in vivo

Neurochemical Research
X H ChenMartin W Adler

Abstract

We examined whether mu-antisense (AS) oligodeoxynucleotide (oligo) treatment can be used in a manner similar to the mu-selective irreversible antagonist beta-funaltrexamine (beta-FNA) for in vivo pharmacology. Rats were injected intracerebroventricularly (icv) with a mu-AS or a missense (MS) oligo on days 1, 3, 5, 7, and 9 and were tested for the antinociceptive effect of sc injection of morphine on days 2, 4, 6, 8, and 10 in the cold water tail-flick (CWT) test. In another set of experiments, rats were also tested for the antinociceptive action of morphine twenty-four hours after icv injection of beta-FNA. Both beta-FNA and mu-AS produced rightward shifts in the dose-effect curves of morphine. In addition, pretreatment with 2.5 micrograms or more of beta-FNA or the mu-AS oligo for 5-9 days (but not for 1-3 days) reduced the maximal analgesic effect of morphine. The approximate fraction of functional receptor remaining for morphine was determined with the method of Furchgott to be 49.5% following 2.5 micrograms of beta-FNA; that after 5 days of the mu-AS oligo treatment was 50.8%. The results suggest that the mu-AS oligo can be used in the same manner as highly selective, irreversible mu opioid receptor ligands. Thus, properly ...Continue Reading

References

Dec 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·B L KiefferC G Hirth
Dec 28, 1992·Science·C J EvansR H Edwards
Aug 11, 1987·European Journal of Pharmacology·L D Recht, G W Pasternak
Jun 1, 1986·Pharmacology, Biochemistry, and Behavior·E B GellerM W Adler
Mar 22, 1985·Science·D J Lipman, W R Pearson
Jun 1, 1987·Irish Journal of Medical Science·W G PowderlyJ R Lennon
Oct 18, 1982·Life Sciences·J S Han, C W Xie
Feb 1, 1994·Trends in Pharmacological Sciences·C Wahlestedt
Mar 3, 1994·European Journal of Pharmacology·C C ChienG W Pasternak
Nov 1, 1993·The Biochemical Journal·S LiL Y Liu-Chen
Jul 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·K YasudaG I Bell

❮ Previous
Next ❯

Citations

Mar 11, 2009·Frontiers in Bioscience (Landmark Edition)·Craig W Stevens
Jan 10, 2018·The Journal of Pharmacology and Experimental Therapeutics·Carol A ParonisJack Bergman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.